Evidence map›Paper›PMID 41427784›Full record

ArticleJCI insight2026

Insights into KIF11 pathogenesis in microcephaly-lymphedema-chorioretinopathy syndrome from a lymphatic perspective.

Kazim Ogmen, Sara E Dobbins, Rose Yinghan Behncke, Ines Martinez-Corral, Ryan Cs Brown, Michelle Meier, Sascha Ulferts, Nils Rouven Hansmeier, Ege Sackey, Ahlam Alqahtani and 17 more

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Kazim OgmenSchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.
Sara E DobbinsSchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.
Rose Yinghan BehnckeResearch Group Lymphovascular Medicine and Translational 3D-Histopathology, Institute of Medical and Human Genetics, Charité - Universitätsmedizin Berlin, Germany.
Ines Martinez-CorralDepartment of Immunology, Genetics and Pathology, Uppsala University, Sweden.
Ryan Cs BrownOrganogenesis and Cancer Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Michelle MeierOrganogenesis and Cancer Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sascha UlfertsResearch Group Lymphovascular Medicine and Translational 3D-Histopathology, Institute of Medical and Human Genetics, Charité - Universitätsmedizin Berlin, Germany.
Nils Rouven HansmeierResearch Group Lymphovascular Medicine and Translational 3D-Histopathology, Institute of Medical and Human Genetics, Charité - Universitätsmedizin Berlin, Germany.
Ege SackeySchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.
Ahlam AlqahtaniBioscience Institute, Wolfson Childhood Cancer Research Centre, Brewery Lane, Newcastle University, Newcastle upon Tyne, United Kingdom.
Christina KarapouliouSchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.
Dionysios GrigoriadisSchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.
Juan C Del Rey JimenezSouth West Thames Centre for Genomics, St George's University Hospitals NHS Foundation Trust, London, United Kingdom.
Michael OberlinFöldiklinik GmbH & Co. KG, European Center for Lymphology Black Forest, Hinterzarten, Germany.
Denise WilliamsThe National Congenital Anomaly and Rare Diseases Registration Services (NCARDRS) NHS England, Birmingham Government Hub, Birmingham, United Kingdom.
Arzu EkiciUniversity of Health Sciences, Bursa Yüksek Īhtisas Training and Research Hospital, Department of Pediatric Neurology, Bursa, Turkey.
Kadri KaraerDepartment of Medical Genetics, Pamukkale University Faculty of Medicine, Denizli, Turkey.
Steve JefferySchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.
Peter MortimerSchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.
Kristiana GordonSchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.
Kazuhide S OkudaOrganogenesis and Cancer Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Benjamin M HoganOrganogenesis and Cancer Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Taija MäkinenDepartment of Immunology, Genetics and Pathology, Uppsala University, Sweden.
René HägerlingResearch Group Lymphovascular Medicine and Translational 3D-Histopathology, Institute of Medical and Human Genetics, Charité - Universitätsmedizin Berlin, Germany.
Sahar MansourSchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.
Silvia Martin-AlmedinaSchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.
Pia OstergaardSchool of Health & Medical Sciences, City St George's, University of London, London, United Kingdom.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Pathogenic variants in kinesin KIF11 underlie microcephaly-lymphedema-chorioretinopathy (MLC) syndrome. Although well known for regulating spindle dynamics ensuring successful cell division, the association of KIF11 (encoding EG5) with development of the lymphatic system and how KIF11 pathogenic variants lead to lymphatic dysfunction and lymphedema remain unknown. Using patient-derived lymphoblastoid cells, we demonstrated that patients with MLC carrying pathogenic stop-gain variants in KIF11 have reduced mRNA and protein levels. Lymphoscintigraphy showed reduced tracer absorption, and intestinal lymphangiectasia was detected in one patient, pointing to impairment of lymphatic function caused by KIF11 haploinsufficiency. We revealed that KIF11 is expressed in early human and mouse development with the lymphatic markers VEGFR3, podoplanin, and PROX1. In zebrafish, single-cell RNA-Seq identified kif11 specifically expressed in endothelial precursors. In human lymphatic endothelial cells, EG5 inhibition with ispinesib reduced VEGFC-driven AKT phosphorylation, migration, and spheroid sprouting. KIF11 knockdown reduced PROX1 and VEGFR3 expression, providing for the first time to our knowledge a link between KIF11 and drivers of lymphangiogenesis and lymphatic identity.

Indexed as

KinesinsLymphedemaMicrocephalyRetinal DiseasesAnimalsEndothelial CellsFemaleHomeodomain ProteinsHumansLymphangiogenesisMaleMiceProspero-Related Homeobox 1 ProteinTumor Suppressor ProteinsVascular Endothelial Growth Factor CVascular Endothelial Growth Factor Receptor-3FLT4 protein, humanHomeodomain ProteinsKIF11 protein, humanKinesinsProspero-Related Homeobox 1 ProteinTumor Suppressor ProteinsVascular Endothelial Growth Factor CVascular Endothelial Growth Factor Receptor-3Cardiovascular diseaseClinical ResearchGeneticsMolecular geneticsVascular biology

Identifiers

PMID41427784
PMCPMC12893108

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.